Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties
Authors:
- 1 November 2014
- journal article
- Published by Elsevier in Life Sciences
- Vol. 117 (2) , 56-66
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Council and National Research Foundation of South Africa (85642, 80647)
This publication has 57 references indexed in Scilit:
- P.2.e.001 Methylene blue for residual symptoms and for cognitive dysfunction in bipolar disorder: results of a double-blind trialEuropean Neuropsychopharmacology, 2011
- Nitric oxide and major depressionNitric Oxide, 2011
- Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c OxidaseJournal of Alzheimer’s Disease, 2010
- Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studiesJournal of Neural Transmission, 2007
- A Neurotrophic Model for Stress-Related Mood DisordersBiological Psychiatry, 2006
- Moclobemide: Therapeutic Use and Clinical StudiesCNS Drug Reviews, 2003
- Antidepressants and neuroplasticityBipolar Disorders, 2002
- Assessing antidepressant activity in rodents: recent developments and future needsTrends in Pharmacological Sciences, 2002
- ANXIOLYTIC AND ANTIDEPRESSANT PROPERTIES OF METHYLENE BLUE IN ANIMAL MODELSPharmacological Research, 1997
- The Monoamine Oxidase Inhibitor—Tyramine InteractionThe Journal of Clinical Pharmacology, 1989